Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1
Introduction: Alzheimer's disease (AD) is the main type of dementia, caused by the accumulation of amyloid plaques, formed by amyloid peptides after being processed from amyloid precursor protein (APP) by γ- and ß-secretases (BACE-1). Although amyloid peptides have been well established for AD,...
Saved in:
Main Authors: | Renata Boldin (Author), Bianca Cestari Zychar (Author), Luis Roberto C. Gonçalves (Author), Juliana Mozer Sciani (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BACE1 Inhibitor, Neuroprotective, and Neuritogenic Activities of Melatonin Derivatives
by: Panyada Panyatip, et al.
Published: (2020) -
Bioassay-guided isolation of BACE1 inhibitors from Crataegus pinnatifida
by: Yajuan Zhou, et al.
Published: (2023) -
The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design
by: Giorgio Cozza
Published: (2017) -
Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders
by: Payyalot Koyiparambath Vishal, et al.
Published: (2021) -
Horse Chestnut Extract. Update-2022
by: Vadim Yu. Bogachev, et al.
Published: (2022)